Evidence map›Paper›PMID 26124876›Full record

ArticleBeilstein journal of organic chemistry2015

Glycodendrimers: tools to explore multivalent galectin-1 interactions.

Jonathan M Cousin, Mary J Cloninger

Open access · diamondAbstract read
In one paragraph

Article in Beilstein journal of organic chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Homo- and Heterogeneous Glycoconjugates on the Basis ofMolecules (Basel, Switzerland) · 2022
    Review
  5. Nanoparticles To Study Lectins inBiomacromolecules · 2021
    Article
  6. Synthesis of Galectin Inhibitors by Regioselective 3'-Molecules (Basel, Switzerland) · 2020
    Article
  7. Article
  8. Review
  9. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.Experimental biology and medicine (Maywood, N.J.) · 2016
    Review
  10. Multivalency as a chemical organization and action principle.Beilstein journal of organic chemistry · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jonathan M CousinDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Mary J CloningerDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Montana State University · US

Funding

Using Dendrimers to Design Multivalent Therapeutic AgentsR01GM062444 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI CLONINGER, MARY J · 2001 to 2015
$3.5M
NIGMS NIH HHS R01 GM062444
6 · The paper itself

Abstract

Four generations of lactose-functionalized polyamidoamine (PAMAM) were employed to further the understanding of multivalent galectin-1 mediated interactions. Dynamic light scattering and fluorescence microscopy were used to study the multivalent interaction of galectin-1 with the glycodendrimers in solution, and glycodendrimers were observed to organize galectin-1 into nanoparticles. In the presence of a large excess of galectin-1, glycodendrimers nucleated galectin-1 into nanoparticles that were remarkably homologous in size (400-500 nm). To understand augmentation of oncologic cellular aggregation by galectin-1, glycodendrimers were used in cell-based assays with human prostate carcinoma cells (DU145). The results revealed that glycodendrimers provided competitive binding sites for galectin-1, which diverted galectin-1 from its typical function in cellular aggregation of DU145 cells.

Indexed as

dendrimergalectin-1glycodendrimermultivalentnanoparticle

Identifiers

PMID26124876
PMCPMC4464428
OpenAlexW2117373900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.